Management ChangeMay 6, 2026, 07:08 AM
Anavex Life Sciences Terminates CEO, Appoints Interim CEO
AI Summary
Anavex Life Sciences Corp. announced the termination of Christopher Missling, PhD, as Chief Executive Officer for Cause, effective April 30, 2026, with a request for his resignation from the Board. The Board subsequently appointed Terrie Kellmeyer, PhD, as Interim Chief Executive Officer on May 4, 2026. Dr. Kellmeyer, with over 30 years of pharmaceutical experience, will receive an annual base salary of $500,000, a 30% annual bonus, a $150,000 signing bonus, and 200,000 stock options. The company also expects to file for an extension for its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
Key Highlights
- Christopher Missling, PhD, terminated as CEO for Cause on April 30, 2026.
- Special Committee requested Dr. Missling's resignation from the Board.
- Terrie Kellmeyer, PhD, appointed Interim Chief Executive Officer on May 4, 2026.
- Dr. Kellmeyer brings over 30 years of pharmaceutical industry experience.
- Her annual base salary is set at $500,000 with an anticipated 30% annual bonus.
- She will receive a one-time cash signing bonus of $150,000.
- She will be awarded 200,000 stock options.
- Company expects to file Form 12b-25 to extend the Q2 2026 Form 10-Q filing date.